S. Emery

A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

Mohammad Tabrizi, Steve Emery, Corinne Reimer, 2010, Molecular Cancer Therapeutics.

Adenovirus vector–mediated delivery of the prodrug-converting enzyme carboxypeptidase G2 in a secreted or GPI-anchored form: High-level expression of this active conditional cytotoxic enzyme at the plasma membrane

S. Emery, D. Blakey, P. Lowenstein, 2002, Cancer Gene Therapy.

A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines

F. Errington, A. Melcher, R. Vile, 2003, Nature Medicine.

Chemotherapy Agents in Preclinical Models Antitumor Activity in Combination with VEGF Inhibitors and A Human Monoclonal Anti-ANG 2 Antibody Leads to Broad

Jeffrey L. Brown, Z. Cao, M. Pinzon-Ortiz, 2009 .

Molecular Cancer Therapeutics A Human Monoclonal Anti-ANG 2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

Jeffrey L. Brown, Z. Cao, M. Pinzon-Ortiz, 2009 .

Discovery of imidazole vinyl pyrimidines as a novel class of kinase inhibitors which inhibit Tie-2 and are orally bioavailable.

S. Emery, C. Forder, D. Buttar, 2008, Bioorganic & medicinal chemistry letters.

Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy

R. Vile, K. Harrington, S. Emery, 2003, Gene Therapy.

Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with activity against Tie-2 in vitro and in vivo.

Peter Ballard, Leonie Campbell, David Buttar, 2009, Bioorganic & medicinal chemistry letters.